Abstract P1-13-02: Withdrawn
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Roberto D’Amico(University of Modena and Reggio Emilia), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Giovanna Cavazzini(University of Padua), Matteo Curtarello(Johannes Gutenberg University Mainz), Patrizia Querzoli(University of Ferrara), Sara Balduzzi(Dutch Cancer Society), Giancarlo Bisagni, Loredana Urso(Istituto Oncologico Veneto), Oriana Nanni(National Institutes of Health), Alessandra Ferro(Istituto Oncologico Veneto), Roberto Vicini, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Enrico Orvieto(AULSS 2 Marca Trevigiana), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Moira Ragazzi(Santa Maria Nuova Hospital), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Nicola Orsi(University of Modena and Reggio Emilia), Elena Bertone, MC Cucchi(University of Modena and Reggio Emilia), MV Dieci(University of Padua), Aa Brandes(University of Modena and Reggio Emilia), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), A. Amadori(University of Modena and Reggio Emilia), Antonino Maiorana(University of Modena and Reggio Emilia)
Cited by 0
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830